DNA — Ginkgo Bioworks Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapNeutral

Annual income statement for Ginkgo Bioworks Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	76.7	314	478	251	227
Cost of Revenue
Gross Profit	61	184	273	197	182
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	214	2,142	2,655	1,158	815
Operating Profit	-137	-1,828	-2,177	-907	-588
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-125	-1,838	-2,121	-893	-548
Provision for Income Taxes
Net Income After Taxes	-127	-1,837	-2,106	-893	-547
Minority Interest
Net Income Before Extraordinary Items
Net Income	-127	-1,830	-2,105	-893	-547
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-127	-1,830	-2,105	-893	-547
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-2.7	-53.8	-49.9	-13.9	-9.23